Clinical proteomics: The application of proteomics in the research of clinical medicine

Progress in Biochemistry and Biophysics

Volumn 33, Issue 1, 2006, Pages 5-9

  Li, Feng ^c   Yang, Fang ^c   Xiao, Zhi Qiang ^a,b   Chen, Zhu Chu ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c Central South University   (China)

Author keywords

Cancer biomarker; Clinical proteomics; Proteomics

Indexed keywords

EID: 33645776944     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Kahn P. From genome to proteome: looking at a cell's proteins. Science, 1995, 270 (5235): 369-370
2. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature, 2003, 422 (6928): 198-207
3. Pandey A, Mann M. Proteomics to study genes and genomes. Nature, 2000, 405 (6788): 837-846
4. Hochstrasser D F. Proteome in perspective. Clin Chem Lab Med, 1998, 36 (11): 825-836
5. Washburn M P, Wolters D, Yates J R, 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol, 2001, 19 (3): 242-247
6. Wu C C, MacCoss M J, Howell K E, et al. A method for the comprehensive proteomic analysis of membrane proteins. Nat Biotechnol, 2003, 21 (5): 532-538
7. Hanash S. Disease proteomics. Nature, 2003, 422 (6928): 226-232
8. Kraemer K H. From proteomics to disease. Nat Genet, 2004, 36 (7): 677-678
9. Petricoin E F, Zoon K C, Kohn E C, et al. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov, 2002, 1 (9): 683-695
10. Petricoin E F, Liotta L A. Proteomic analysis at the bedside: early detection of cancer. Trends Biotechnol, 2002, 20 (12 Suppl): S30-34
11. Hanash S. HUPO initiatives relevant to clinical proteomics. Mol Cell Proteomics, 2004, 3 (4): 298-301
12. Johann D J, Jr., McGuigan M D, Patel A R, et al. Clinical proteomics and biomarker discovery. Ann N Y Acad Sci, 2004, 1022: 295-305
13. Wulfkuhle J D, Liotta L A, Petricoin E F. Proteomic applications for the early detection of cancer. Nat Rev Cancer, 2003, 3 (4): 267-275
14. Rai A J, Zhang Z, Rosenzweig J, et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med, 2002, 126(12): 1518-1526
15. Zhang Z, Bast R C, Jr., Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res, 2004, 64 (16): 5882-5890
16. Colantonio D A, Chan D W. The clinical application of proteomics. Clin Chim Acta, 2005, 357 (2): 151-158
17. Rai A J, Gelfand C A, Haywood B C, et al. HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples. Proteomics, 2005, 5(13): 3262-3277
18. White C N, Chan D W, Zhang Z. Bioinformatics strategies for proteomic profiling. Clin Biochem, 2004, 37 (7): 636-641
19. Emmert-Buck M R, Bonner R F, Smith P D, et al. Laser capture microdissection. Science, 1996, 274 (5289): 998-1001
20. Liotta L A, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature, 2003, 425 (6961): 905
21. Ostergaard M, Rasmussen H H, Nielsen H V, et al. Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res, 1997, 57 (18): 4111-4117
22. Zhou G, Li H M, DeCamp D, et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Molecular Cellular Proteomics, 2002, 1 (2): 117-124
23. Le Naour F. Contribution of proteomics to tumor immunology. Proteomics, 2001, 1 (10): 1295-1302
24. Seliger B, Kellner R. Design of proteome-based studies in combination with serology for the identification of biomarkers and novel targets. Proteomics, 2002, 2 (12): 1641-1651
25. Merchant M, Weinberger S R. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis, 2000, 21 (6): 1164-1177
26. Petricoin E F, Ardekani A M, Hitt B A, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 2002, 359 (9306): 572-577
27. Paweletz C P, Charboneau L, Bichsel V E, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene, 2001, 20 (16): 1981-1989